Most patients find the injections virtually painless and easy to administer at home
Even with IV therapy: Early brightness effects may appear in 24 weeks Visible changes often require multiple sessions over several months The body still needs time to influence melanin pathways and skin turnover cycles
Appointments, evaluations, and treatment management are handled through an easy-to-use online platform, reducing the need for repeated office visits while maintaining physician oversight
The interaction between semaglutide and SSRIs may be attributed to pharmacokinetic and pharmacodynamic mechanisms
When broader nutritional support or hydration is the goal, IV infusions justify the premium through their expanded scope of delivery
In China, beyond the in-market products such as semaglutide and tirzepatide and promising global pipeline assets including orforglipron (oral), MariTide (monthly injectable) and retatrutide (triple agonist), a range of China-only molecules is also emerging with strong competitiveness (see Table 2)